Motes early tumor dissemination by way of complexing with activated 1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 33:25568. 17. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM (2009) The transmembrane src substrate Trask is definitely an epithelial protein that signals in the course of anchorage deprivation. Am J Pathol 174:1756765. 18. Conze T, et al. (2003) CDCP1 is really a novel marker for hematopoietic stem cells. Ann N Y Acad Sci 996:22226. 19. B ring HJ, et al. (2004) CDCP1 identifies a broad spectrum of regular and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells 22:33443. 20. Uekita T, Sakai R (2011) Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis.Price of 173315-56-5 Cancer Sci 102:1943948.E6920 | www.pnas.org/cgi/doi/10.1073/pnas.Enyindah-Asonye et al.21. Perry SE, et al. (2007) Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 581:1137142. 22. Uekita T, et al. (2008) CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 172:1729739. 23. Awakura Y, et al. (2008) Microarray-based identification of CUB-domain containing protein 1 as a prospective prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134:1363369.89336-46-9 Purity 24. Razorenova OV, et al. (2011) VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCdelta-driven migration. Proc Natl Acad Sci USA 108:1931936. 25. Wong CH, et al. (2009) Phosphorylation with the SRC epithelial substrate Trask is tightly regulated in typical epithelia but widespread in numerous human epithelial cancers. Clin Cancer Res 15:2311322. 26. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM (2013) Trask loss enhances tumorigenic development by liberating integrin signaling and growth issue receptor crosstalk in unanchored cells. Cancer Res 73:1168179. 27. Jayaraman K (2013) Biocon’s first-in-class anti-CD6 mAb reaches the marketplace. Nat Biotechnol 31:1062063. 28. Seidel J, Bruemann C, Kunc K, Possinger K, Lueftner D (2009) Evaluation of CUBdomain-containing protein (CDCP1)-expression as predictive marker of adhesionindependent cell survival in breast cancer cell lines. Cancer Res 69:6167. 29. Wortmann A, et al. (2011) Cellular settings mediating Src Substrate switching among focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem 286:423032315. 30. Kollmorgen G, et al. (2013) Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol 7:1142151. 31. Ikeda JI, et al.PMID:23551549 (2006) Epigenetic regulation with the expression on the novel stem cell marker CDCP1 in cancer cells. J Pathol 210:754. 32. Spassov DS, et al. (2011) Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol 31: 76682. 33. Lunter Pc, et al. (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/ MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65:8801808. 34. Miyazawa Y, et al. (2010) CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70:5136146. 35. Li Y, et al. (2017) CD6 as a potential target for treating a number of sclerosis. Proc Natl Acad Sci USA 114:2687692. 36. Singer NG, et al. (1997) CD6.